Previous close | 100.00 |
Open | 97.76 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 100.00 - 100.00 |
52-week range | 86.12 - 110.45 |
Volume | |
Avg. volume | 40,557 |
Market cap | 124.823B |
Beta (5Y monthly) | 0.45 |
PE ratio (TTM) | 25.84 |
EPS (TTM) | 3.87 |
Earnings date | 25 Jul 2024 |
Forward dividend & yield | 4.06 (4.06%) |
Ex-dividend date | 13 May 2024 |
1y target est | N/A |
Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.
Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the 2023-2024 RSV season, versus no intervention1-6Results add to the consistent high efficacy of Beyfortus against medically attended RSV lower respiratory tract disease, shown in the pivotal clinical studies and the outcomes from HARMONIE, a p
Sanofi (NASDAQ:SNY) Q1 2024 Earnings Call Transcript April 25, 2024 Sanofi reports earnings inline with expectations. Reported EPS is $0.96 EPS, expectations were $0.96. Sanofi isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Paul Hudson: Welcome to the Q1 2024 conference […]